



HYDE PARK CAPITAL

Integrity | Expertise | Results

Investment Banking | Mergers & Acquisitions | Capital Raising

Overview

Nationally recognized investment bank
founded in 2000

Over 300 transactions completed, totaling
more than \$10 billion in transaction value

Extensive relationships with leading
institutional lenders, PE investors,
and strategic buyers

Proven ability to source quality buyers
and maximize deal value

Industry Expertise

- Technology
- Healthcare
- Business Services
- Industrial Services
- Financial Services
- Consumer

Transaction Size

- \$25MM - \$500MM

Investment Banking Services

Mergers & acquisitions, recapitalizations,
and management buyouts

Capital raising of equity, mezzanine, and
senior debt capital

Financial advisory, analytical support,
and fairness opinions

Comprehensive and targeted sell-side
marketing efforts

Hyde Park Capital Advisors, LLC

701 N. Franklin Street
Tampa, FL 33602
Tel: 813-383-0202

www.hydeparkcapital.com

Healthcare **M&A Report** *Q1 2019*



Capital Markets Overview – Healthcare


Commentary

- ❑ The Nasdaq Health Care Index increased 14.0% during the twelve month period ended March 31, 2019, while the Nasdaq and the S&P 500 increased 12.5% and 9.8%, respectively.
- ❑ The table to the right highlights select public offerings completed in the *Healthcare* industry during Q1 2019. Gossamer Bio, Inc. (NasdaqGS:GOSS), a clinical-stage biopharmaceutical company, completed the largest IPO during the quarter, raising \$276 million.
- ❑ The *Healthcare Equipment & Supplies*, *Life Sciences Tools & Services*, and *Healthcare Technology* sectors remained the industry's leaders with respect to valuation, trading at EBITDA multiples of 21.5x, 21.3x, and 20.1x, respectively.

Select Public Offerings – Healthcare (Q1 2019)

Offer Date	Issuer	Industry Sector	Offering Type	Offering Size (\$MM)
03/27/19	Precision BioSciences, Inc.	Biotechnology	IPO	\$126
03/26/19	IntelliCentrics Global Holdings Ltd.	Healthcare Technology	IPO	\$55
03/06/19	ShockWave Medical, Inc.	Healthcare Equipment & Supplies	IPO	\$97
02/27/19	Kaleido BioSciences, Inc.	Pharmaceuticals	IPO	\$75
02/14/19	Stealth BioTherapeutics Corp.	Biotechnology	IPO	\$78
02/13/19	TCR2 Therapeutics, Inc.	Biotechnology	IPO	\$75
02/13/19	Avedro, Inc.	Healthcare Equipment & Supplies	IPO	\$70
02/11/19	Cansortium, Inc.	Pharmaceuticals	IPO	\$52
02/07/19	Gossamer Bio, Inc.	Biotechnology	IPO	\$276
02/06/19	Alector, Inc.	Biotechnology	IPO	\$176

Public Market Performance (LTM)



Source: S&P Capital IQ.

Public Company Market Performance by Sector

Industry Sector	Change in Stock Price		Median Enterprise Value / LTM	
	3 Months	12 months	Revenue	EBITDA
Healthcare Equipment & Supplies	26.2%	22.7%	5.2x	21.5x
Healthcare Distribution	0.5%	(13.8%)	0.2x	8.3x
Healthcare Services	10.5%	(13.1%)	1.8x	11.2x
Healthcare Facilities	8.1%	26.1%	1.4x	9.8x
Managed Healthcare	2.8%	14.0%	0.5x	9.6x
Healthcare Technology	9.7%	2.2%	2.7x	20.1x
Pharmaceuticals	1.0%	16.4%	3.4x	11.7x
Biotechnology	4.4%	3.2%	4.2x	13.6x
Life Sciences Tools & Services	26.2%	32.3%	4.9x	21.3x



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Quarterly Middle-Market M&A Activity – Healthcare

Commentary


- Middle-market M&A activity in the *Healthcare* industry continued to slow during Q1 2019 to 54 closed transactions – a 10% decrease from the 60 closed transactions during the prior year period.
- The total value of deals closed in the middle market fell 36% to \$7.0 billion in Q1 2019, down from \$10.9 billion the prior year period, in large part due to the dramatic decrease in deals valued between \$500 million and \$999 million. Increased deal value was seen in transactions valued less than \$500 million.
- Although middle market deal activity was down, deal volume for all transactions (including those with undisclosed values) increased 3.4% in Q1 2019, with 339 closed deals compared to the prior year period's 328 closed deals.

Middle-Market M&A Transactions by Deal Size – Healthcare


(\$ in billions)

Deal Size	Q1 2018		Q1 2019		% Change	
	Volume	Value	Volume	Value	Volume	Value
Less than \$100MM	31	\$0.9	33	\$1.2	6%	33%
\$100 - \$499MM	21	\$4.0	20	\$5.3	(5%)	33%
\$500 - \$999MM	8	\$6.0	1	\$0.5	(88%)	(92%)
Total Middle Market	60	\$10.9	54	\$7.0	(10%)	(36%)
% of Middle Market						
Less than \$100MM	52%	8%	61%	17%		
\$100 - \$499MM	35%	37%	37%	76%		
\$500 - \$999MM	13%	55%	2%	7%		
Total Middle Market	100%	100%	100%	100%		

U.S. Middle-Market M&A Activity – Quarterly Trends: VOLUME



U.S. Middle-Market M&A Activity – Quarterly Trends: VALUE



Source: Capital IQ. Includes deals with disclosed values greater than \$10 million. Note: Due to rounding, numbers may not sum precisely.



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Recent M&A Activity – Healthcare

Select Announced M&A Transactions (Q1 2019)

Announced Date	Target	Buyer	Industry	Transaction Value (\$MM)	EV / Revenue	EV / EBITDA
03/27/19	WellCare Health Plans, Inc.	Centene	Managed Healthcare	\$15,620	NA	NA
03/24/19	Brammer Bio, LLC	Thermo Fisher Scientific	Biotechnology	\$1,700	NA	NA
03/18/19	Acres Cannabis	Curaleaf Holdings	Pharmaceuticals	\$70	NA	NA
03/14/19	DCP Holding Co.	DentaQuest	Managed Healthcare	\$42	NA	NA
03/12/19	Osiris Therapeutics, Inc.	Smith & Nephew	Biotechnology	\$660	4.4x	60.6x
03/11/19	Verano Holdings, LLC	Harvest Health & Recreation	Pharmaceuticals	\$850	NA	NA
03/05/19	Prescribe Wellness, LLC	Tabula Rasa HealthCare	Healthcare Technology	\$150	5.2x	NA
02/25/19	General Electric Co. BioPharma Business	Danaher	Life Sciences Tools & Services	\$21,400	7.1x	NA
02/25/19	Spark Therapeutics, Inc.	Roche Holding	Biotechnology	\$4,851	67.9x	NA
02/21/19	Immune Design Corp.	Merck Sharp & Dohme	Biotechnology	\$296	91.1x	NA
01/28/19	Thermo Fisher Scientific, Inc. Anatomical Pathology Business	PHC Holdings	Life Sciences Tools & Services	\$1,140	3.3x	NA
01/28/19	Geneva Healthcare, Inc.	BioTelemetry	Healthcare Technology	\$65	10.8x	NA
01/16/19	Fuse Medical, Inc.	Generex Biotechnology	Healthcare Distribution	\$34	NA	NA
01/07/19	Loxo Oncology, Inc.	Eli Lilly	Biotechnology	\$8,013	51.0x	NA
01/03/19	Celgene Corp.	Bristol-Myers Squibb	Biotechnology	\$99,554	6.1x	15.3x

Source: Capital IQ.




HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

M&A Activity by Healthcare Sector


U.S. Deal Flow by Healthcare Sector

All reported deals:



U.S. Middle Market* Deal Flow by Healthcare Sector

Deals with reported value:



Source: Capital IQ (includes closed deals with values between \$10MM and \$1B). Managed HC and HC Distribution are included in HC Services sector. *Includes closed deals with values between \$10MM and \$1B.



HYDE PARK CAPITAL


Investment Banking | Mergers & Acquisitions | Capital Raising

Private Equity Activity – Healthcare

Commentary

- Financial sponsor activity in the *Healthcare* industry experienced an uptick during Q1 2019 with 55 deals announced – up from the 46 deals announced in Q4 2018. As dry powder remains near all-time highs and pressure to deploy capital has driven price multiples upward, financial sponsors have begun moving down-market in an effort to alleviate competition.
- Several notable private equity-backed deals were announced during the quarter, including H.I.G. Capital's closed acquisition of Taconic Biosciences, Inc. and Bain Capital/Summit Partner's announced acquisition of U.S. Renal Care, Inc.
- The *Healthcare Facilities* sector was the most active in the industry with 26 deals announced during Q1 2019.

Financial Sponsors Activity by Sector



Select Announced Private Equity M&A Transactions (Q1 2019)

Announced Date	Target	Buyer	Industry
03/19/19	Visual Healthcare Corp.	LTN Capital	Healthcare Technology
03/18/19	Center for Diagnostic Imaging, Inc.	Wellspring Capital	Healthcare Services
03/15/19	Proud Moments Licensed Behavior Analysts, LLC	Audax Group	Healthcare Services
02/25/19	Compassion-First Pet Hospitals	JAB Holding Co.	Healthcare Facilities
02/23/19	Five Zero Trees, Inc.	Groundworks Industries	Pharmaceuticals
02/22/19	Dr. Dental	ABRY Partners	Healthcare Services
02/21/19	Restorative Therapies, Inc.	1315 Capital	Healthcare Equipment & Supplies
02/13/19	U.S. Renal Care, Inc.	Bain Capital/Summit Partners	Healthcare Facilities
02/11/19	Qualcomm Life, Inc.	Francisco Partners	Healthcare Technology
02/07/19	Taconic Biosciences, Inc.	H.I.G. Capital	Biotechnology
02/05/19	YPrime, Inc.	Ballast Point Ventures/Edwards Capital	Healthcare Technology
02/05/19	Simply Beautiful Smiles	Sun Capital	Healthcare Services
02/04/19	Syneo, LLC	RockWood Equity	Life Sciences Tools & Services
01/29/19	Georgia Pain & Wellness Center	Fulcrum Equity	Healthcare Services
01/21/19	Orchid Orthopedic Solutions, LLC	Nordic Capital	Healthcare Equipment & Supplies
01/15/19	Cochran Wholesale Pharmaceutical, Inc.	Trive Capital	Healthcare Distribution
01/03/19	Healthdrive Corp.	Bain Capital	Healthcare Services

Source: Capital IQ. Includes transactions with undisclosed transaction values. Financial sponsors include private & public investment firms, and corporate & financial service investment arms.



HYDE PARK CAPITAL


Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Recent Stock Price Performance


Commentary

- ❑ The charts included on the following pages detail the recent stock price performance by sector for the leading public companies within the *Healthcare* industry for the 12-month period ended March 31, 2019. The shaded section represents Q1 2019.
- ❑ Over that period, the majority of the industry's sectors had positive performances. The sectors which saw the largest increases included *Life Sciences Tools & Services*, *Healthcare Facilities*, and *Healthcare Equipment & Supplies*, which increased 32.3%, 26.1%, and 22.7%, respectively.
- ❑ The sectors that saw decreases were *Healthcare Distribution* and *Healthcare Services*, which decreased 13.8% and 13.1%, respectively.


Healthcare Services



Healthcare Facilities



Managed Healthcare



Source: Capital IQ.




HYDE PARK CAPITAL


Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Recent Stock Price Performance


Healthcare Technology




Healthcare Equipment & Supplies



Healthcare Distribution



Pharmaceuticals



Source: Capital IQ.




HYDE PARK CAPITAL


Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Recent Stock Price Performance

Biotechnology



Life Sciences Tools & Services



Source: Capital IQ.



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Public Company Analysis

(\$ in millions, except per share)

Healthcare Facilities

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
HCA Holdings, Inc.	HCA	\$130.38	88.4%	\$46,324	\$80,675	\$46,677	\$17,528	\$8,920	37.6%	19.1%	1.7x	9.0x
Tenet Healthcare Corp.	THC	\$28.84	72.6%	\$2,934	\$19,494	\$18,672	\$6,870	\$2,629	36.8%	14.1%	1.0x	7.4x
Universal Health Services, Inc.	UHS	\$133.77	94.1%	\$12,615	\$16,633	\$10,661	\$4,330	\$1,703	40.6%	16.0%	1.6x	9.8x
Encompass Health Corp.	EHC	\$58.40	70.8%	\$5,825	\$8,811	\$4,195	\$1,743	\$881	41.6%	21.0%	2.1x	10.0x
Select Medical Holdings Corp.	SEM	\$14.09	65.1%	\$1,832	\$5,917	\$4,910	\$975	\$600	19.9%	12.2%	1.2x	9.9x
Hanger Orthopedic Group, Inc.	HNGR	\$19.05	77.8%	\$698	\$1,149	\$1,050	\$351	\$93	33.5%	8.8%	1.1x	12.4x
Average			78.1%	\$11,705	\$22,113	\$14,361	\$5,300	\$2,471	35.0%	15.2%	1.5x	9.7x
Median			75.2%	\$4,380	\$12,722	\$7,785	\$3,037	\$1,292	37.2%	15.0%	1.4x	9.8x

Healthcare Services

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Laboratory Corp. of America Holdings	LH	\$152.98	80.4%	\$15,696	\$21,351	\$11,333	\$3,176	\$1,907	28.0%	16.8%	1.9x	11.2x
DaVita, Inc.	DVA	\$54.29	68.6%	\$9,358	\$20,464	\$11,412	\$3,217	\$2,081	28.2%	18.2%	1.8x	9.8x
Quest Diagnostics, Inc.	DGX	\$89.92	77.2%	\$12,431	\$16,872	\$7,538	\$2,661	\$1,503	35.3%	19.9%	2.2x	11.2x
MEDNAX, Inc.	MD	\$27.17	48.1%	\$2,489	\$4,405	\$3,647	\$1,032	\$557	28.3%	15.3%	1.2x	7.9x
RadNet, Inc.	RDNT	\$12.39	74.9%	\$603	\$1,335	\$975	\$197	\$106	20.2%	10.9%	1.4x	12.6x
Average			69.8%	\$8,115	\$12,885	\$6,981	\$2,057	\$1,231	28.0%	16.2%	1.7x	10.5x
Median			74.9%	\$9,358	\$16,872	\$7,538	\$2,661	\$1,503	28.2%	16.8%	1.8x	11.2x

Source: Capital IQ



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Public Company Analysis

(\$ in millions, except per share)

Managed Healthcare

Company	Ticker	Closing Price	% of 52	Equity	Enterprise	LTM			LTM Margins		Enterprise Value /	
		3/29/19	Week High	Value	Value	Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Unitedhealth Group, Inc.	UNH	\$247.26	85.9%	\$243,057	\$267,195	\$226,247	\$53,846	\$19,772	23.8%	8.7%	1.2x	13.5x
Anthem, Inc.	ANTM	\$286.98	90.2%	\$75,820	\$73,495	\$92,105	\$20,210	\$6,959	21.9%	7.6%	0.8x	10.6x
Cigna Corp.	CI	\$160.82	71.0%	\$39,656	\$40,602	\$44,542	\$15,031	\$5,151	33.7%	11.6%	0.9x	7.9x
Humana, Inc.	HUM	\$266.00	74.7%	\$37,144	\$28,678	\$55,933	\$10,845	\$3,549	19.4%	6.3%	0.5x	8.1x
Centene Corp.	CNC	\$53.10	71.3%	\$10,148	\$9,345	\$52,615	\$9,997	\$2,373	19.0%	4.5%	0.2x	3.9x
WellCare Health Plans, Inc.	WCG	\$269.75	83.0%	\$12,409	\$9,193	\$18,688	\$2,825	\$808	15.1%	4.3%	0.5x	11.4x
Magellan Health Services, Inc.	MGLN	\$65.92	58.7%	\$1,664	\$2,231	\$7,164	\$282	\$233	3.9%	3.2%	0.3x	9.6x
Average			76.4%	\$59,985	\$61,534	\$71,042	\$16,148	\$5,549	19.6%	6.6%	0.6x	9.3x
Median			74.7%	\$37,144	\$28,678	\$52,615	\$10,845	\$3,549	19.4%	6.3%	0.5x	9.6x

Healthcare Technology

Company	Ticker	Closing Price	% of 52	Equity	Enterprise	LTM			LTM Margins		Enterprise Value /	
		3/29/19	Week High	Value	Value	Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Cerner Corp.	CERN	\$57.21	84.7%	\$19,084	\$18,752	\$5,366	\$4,429	\$1,207	82.5%	22.5%	3.5x	15.5x
NextGen Healthcare, Inc.	NXGN	\$16.83	70.9%	\$1,083	\$1,081	\$530	\$288	\$39	54.4%	7.3%	2.0x	27.8x
Healthstream, Inc.	HSTM	\$28.06	88.1%	\$909	\$794	\$242	\$141	\$32	58.4%	13.3%	3.3x	24.7x
Computer Programs & Systems, Inc.	CPSI	\$29.69	85.7%	\$403	\$528	\$280	\$150	\$34	53.4%	12.2%	1.9x	15.5x
Average			82.3%	\$5,370	\$5,289	\$1,605	\$1,252	\$328	62.2%	13.8%	2.7x	20.9x
Median			85.2%	\$996	\$938	\$405	\$219	\$37	56.4%	12.7%	2.7x	20.1x

Source: Capital IQ.



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Public Company Analysis

(\$ in millions, except per share)

Healthcare Equipment & Supplies

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Medtronic, Inc.	MDT	\$91.08	90.9%	\$123,974	\$139,977	\$30,555	\$21,598	\$9,676	70.7%	31.7%	4.6x	14.5x
Becton, Dickinson and Co.	BDX	\$249.73	93.9%	\$68,844	\$88,969	\$17,063	\$8,218	\$5,084	48.2%	29.8%	5.2x	17.5x
Stryker Corp.	SYK	\$197.52	99.4%	\$75,048	\$81,240	\$13,876	\$9,127	\$3,777	65.8%	27.2%	5.9x	21.5x
The Cooper Companies, Inc.	COO	\$296.17	99.1%	\$14,794	\$16,780	\$2,571	\$1,717	\$782	66.8%	30.4%	6.5x	21.5x
Teleflex, Inc.	TFX	\$302.16	98.8%	\$14,141	\$15,936	\$2,448	\$1,420	\$667	58.0%	27.2%	6.5x	23.9x
Varian Medical Systems, Inc.	VAR	\$141.72	99.7%	\$13,123	\$12,472	\$2,982	\$1,287	\$562	43.2%	18.8%	4.2x	22.2x
Steris Corp.	STE	\$128.03	99.5%	\$10,946	\$11,975	\$2,730	\$1,135	\$634	41.6%	23.2%	4.4x	18.9x
Average			97.3%	\$45,839	\$52,478	\$10,318	\$6,357	\$3,026	56.3%	26.9%	5.3x	20.0x
Median			99.1%	\$14,794	\$16,780	\$2,982	\$1,717	\$782	58.0%	27.2%	5.2x	21.5x

Healthcare Distribution

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
McKesson Corp.	MCK	\$117.06	72.8%	\$23,383	\$32,926	\$213,518	\$11,628	\$4,034	5.4%	1.9%	0.2x	8.2x
Cardinal Health, Inc.	CAH	\$48.15	72.5%	\$15,023	\$21,979	\$139,381	\$7,176	\$2,947	5.1%	2.1%	0.2x	7.5x
AmerisourceBergen Corp.	ABC	\$79.52	83.7%	\$17,385	\$19,010	\$172,866	\$4,761	\$2,240	2.8%	1.3%	0.1x	8.5x
Henry Schein, Inc.	HSIC	\$60.11	65.8%	\$9,290	\$12,054	\$13,145	\$3,586	\$1,106	27.3%	8.4%	0.9x	10.9x
Patterson Companies, Inc.	PDCO	\$21.85	82.1%	\$2,028	\$2,688	\$5,517	\$1,163	\$221	21.1%	4.0%	0.5x	12.2x
Owens & Minor, Inc.	OMI	\$4.10	21.4%	\$246	\$1,762	\$9,686	\$1,345	\$240	13.9%	2.5%	0.2x	7.3x
Average			66.4%	\$11,226	\$15,070	\$92,352	\$4,943	\$1,798	12.6%	3.4%	0.3x	9.1x
Median			72.6%	\$12,156	\$15,532	\$76,263	\$4,174	\$1,673	9.7%	2.3%	0.2x	8.3x

Source: Capital IQ.



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Public Company Analysis

(\$ in millions, except per share)

Pharmaceuticals

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Pfizer Inc.	PFE	\$42.47	91.4%	\$253,843	\$278,581	\$53,647	\$42,519	\$22,705	79.3%	42.3%	5.2x	12.3x
Eli Lilly and Co.	LLY	\$129.76	98.2%	\$134,642	\$139,413	\$24,278	\$17,877	\$7,789	73.6%	32.1%	5.7x	17.9x
Bristol-Myers Squibb Co.	BMJ	\$47.71	74.9%	\$78,101	\$78,688	\$22,561	\$16,072	\$7,115	71.2%	31.5%	3.5x	11.1x
Mylan N.V.	MYL	\$28.34	66.7%	\$14,774	\$28,702	\$11,594	\$4,722	\$3,777	40.7%	32.6%	2.5x	7.6x
Catalent, Inc.	CTLT	\$40.59	87.4%	\$5,552	\$7,565	\$2,471	\$761	\$506	30.8%	20.5%	3.1x	15.0x
Amneal Pharmaceuticals, Inc.	AMRX	\$14.17	57.9%	\$1,804	\$4,926	\$1,459	\$733	\$444	50.2%	30.5%	3.4x	11.1x
Prestige Brands Holdings, Inc.	PBH	\$29.91	71.6%	\$1,586	\$3,445	\$1,020	\$576	\$343	56.4%	33.6%	3.4x	10.0x
ANI Pharmaceuticals, Inc.	ANIP	\$70.54	96.9%	\$821	\$982	\$192	\$127	\$73	66.2%	38.0%	5.1x	13.5x
Average			80.6%	\$61,391	\$67,788	\$14,653	\$10,423	\$5,344	58.6%	32.6%	4.0x	12.3x
Median			81.2%	\$10,163	\$18,134	\$7,033	\$2,741	\$2,141	61.3%	32.3%	3.4x	11.7x

Biotechnology

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Amgen, Inc.	AMGN	\$189.98	90.4%	\$126,337	\$130,962	\$23,747	\$19,646	\$12,497	82.7%	52.6%	5.5x	10.5x
Celgene Corp.	CELG	\$94.34	99.0%	\$69,227	\$83,448	\$15,281	\$14,062	\$6,124	92.0%	40.1%	5.5x	13.6x
Gilead Sciences, Inc.	GILD	\$65.01	81.7%	\$85,033	\$81,791	\$22,127	\$17,274	\$10,449	78.1%	47.2%	3.7x	7.8x
Biogen, Inc.	BIIB	\$236.38	60.8%	\$47,660	\$50,130	\$13,812	\$11,839	\$7,109	85.7%	51.5%	3.6x	7.1x
Alexion Pharmaceuticals, Inc.	ALXN	\$135.18	96.0%	\$30,348	\$31,989	\$4,131	\$3,763	\$2,000	91.1%	48.4%	7.7x	16.0x
Emergent Biosolutions, Inc.	EBS	\$50.52	68.4%	\$2,597	\$3,279	\$782	\$317	\$173	40.6%	22.1%	4.2x	19.0x
Eagle Pharmaceuticals, Inc.	EGRX	\$50.49	58.9%	\$771	\$737	\$213	\$151	\$50	71.0%	23.5%	3.5x	14.7x
Average			79.3%	\$51,710	\$54,619	\$11,442	\$9,579	\$5,486	77.3%	40.8%	4.8x	12.7x
Median			81.7%	\$47,660	\$50,130	\$13,812	\$11,839	\$6,124	82.7%	47.2%	4.2x	13.6x

Source: Capital IQ.



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising

Industry Sector Overview – Public Company Analysis

(\$ in millions, except per share)

Life Sciences Tools & Services

Company	Ticker	Closing Price 3/29/19	% of 52 Week High	Equity Value	Enterprise Value	LTM			LTM Margins		Enterprise Value / LTM	
						Revenue	Gross Profit	EBITDA	Gross Profit	EBITDA	Revenue	EBITDA
Thermo Fisher Scientific Inc.	TMO	\$273.72	99.9%	\$111,130	\$128,017	\$24,358	\$11,379	\$6,124	46.7%	25.1%	5.3x	20.9x
Agilent Technologies, Inc.	A	\$80.38	97.7%	\$26,124	\$25,680	\$4,914	\$2,687	\$1,184	54.7%	24.1%	5.2x	21.7x
Mettler-Toledo International Inc.	MTD	\$723.00	98.7%	\$18,774	\$19,682	\$2,896	\$1,660	\$717	57.3%	24.8%	6.8x	27.4x
Waters Corp.	WAT	\$251.71	99.8%	\$19,537	\$18,950	\$2,420	\$1,427	\$850	59.0%	35.1%	7.8x	22.3x
PerkinElmer, Inc.	PKI	\$96.36	98.0%	\$10,747	\$12,476	\$2,778	\$1,341	\$516	48.3%	18.6%	4.5x	24.2x
Syneos Health, Inc.	SYNH	\$51.76	91.9%	\$5,366	\$8,109	\$3,995	\$1,866	\$489	46.7%	12.2%	2.0x	16.6x
Medpace Holdings, Inc.	MEDP	\$58.97	82.3%	\$2,184	\$2,302	\$612	\$372	\$126	60.8%	20.7%	3.8x	18.2x
Luminex Corp.	LMNX	\$23.01	65.1%	\$1,013	\$866	\$313	\$198	\$60	63.1%	19.0%	2.8x	14.6x
Average			91.7%	\$24,360	\$27,010	\$5,286	\$2,616	\$1,258	54.6%	22.5%	4.8x	20.7x
Median			97.8%	\$14,761	\$15,713	\$2,837	\$1,544	\$617	56.0%	22.4%	4.9x	21.3x

Source: Capital IQ.



HYDE PARK CAPITAL

Investment Banking | Mergers & Acquisitions | Capital Raising



HYDE PARK CAPITAL

Integrity | Expertise | Results

Investment Banking | Mergers & Acquisitions | Capital Raising

Overview

Nationally recognized investment bank founded in 2000

Over 300 transactions completed, totaling more than \$10 billion in transaction value

Extensive relationships with leading institutional lenders, PE investors, and strategic buyers

Proven ability to source quality buyers and maximize deal value

Industry Expertise

- Technology
- Business Services
- Financial Services
- Healthcare
- Industrial Services
- Consumer

Transaction Size

- \$25MM - \$500MM

Investment Banking Services

Mergers & acquisitions, recapitalizations, and management buyouts

Capital raising of equity, mezzanine, and senior debt capital

Financial advisory, analytical support, and fairness opinions

Comprehensive and targeted sell-side marketing efforts

Hyde Park Capital Advisors, LLC

701 N. Franklin Street

Tampa, FL 33602

Tel: 813-383-0202

www.hydeparkcapital.com

Recent Transactions

Industrial Truck & Equipment, LLC

has acquired



has been acquired by



received a strategic investment from



has been acquired by



has been acquired by



a subsidiary of



has been acquired by



has been recapitalized by



has been acquired by



has been acquired by



has been acquired by



has been recapitalized by



&



has been recapitalized by



&



has been acquired by



has received a growth equity investment from



has been acquired by

